Drug Approval | July 08, 2022
Lupin’s Somerset manufacturing plant Receives EIR from US FDA
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Company is investing more than €100 million in the expansion of the Halle site
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Tislelizumab is now approved in nine indications in China
Bayer now present in four of the largest biotechnology hubs in the United States
Subscribe To Our Newsletter & Stay Updated
